As published by ‘Dutch News’, Code Pharma has reported positive results from an eight-week study of its HIV treatment candidate, Gammora, suggesting it may provide a cellular-level approach to curing HIV. The preliminary findings were presented at the 2024 HIV Drug Therapy Conference in Glasgow, Scotland.
Gammora, a peptide derived from HIV-1 integrase, is designed to target HIV by promoting the insertion of viral genetic material into infected cells. In a pilot open-label, randomized trial, Gammora combined with protease inhibitor (PI)-based antiretroviral therapy (ART) demonstrated a safe and effective reduction in the HIV reservoir—cells infected with the virus—without damaging healthy cells, a common limitation of standard ART treatments.
Building on this progress, Code Pharma will present updated data and preview an upcoming clinical trial protocol for Gammora at the HIV Persistence During Therapy Workshop in Miami, Florida.